Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of alpha(2) and 5-HT(1A) receptors
by
Owen JC, Whitton PS.
Department of Pharmacology,
The School of Pharmacy,
29-39 Brunswick Square,
WC1N 1AX, London, UK
Neurosci Lett. 2003 Sep 18;348(3):171-174

ABSTRACT

The effect of reboxetine on norepinephrine (NE) efflux in the frontal cortex of freely moving rats has been studied using in vivo microdialysis. Reboxetine was administered either by injection (10 and 30 mg/kg i.p.) or directly to the frontal cortex via the dialysis probe (10 and 100 microM). To further elucidate the mechanism of action of reboxetine in this region yohimbine (10 microM) was co-infused with reboxetine via the frontal cortex probe. Both routes of administration of reboxetine resulted in a drug-induced, dose-dependent decrease in frontal cortex NE efflux. This effect was reversed following co-infusion of yohimbine, which has been shown to possess both alpha(2)-adrenoceptor antagonist and 5-HT(1A) agonist properties.

Efficacy
Reboxetine
Noradrenaline
NARIs and SSRIs
Dopamine reuptake inhibition
Reboxetine and major depression
Reboxetine and social functioning
Depression, antidepressants and noradrenaline
Reboxetine (Edronax, Vestra) and social functioning

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family